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Abstract 
Study hypothesis: We wanted to probe the opinions and current practices on 
preimplantation genetic screening (PGS), and more specifically on PGS in its newest form: 
PGS 2.0. 
Study finding: Consensus is lacking on which patient groups, if any at all, can benefit from 
PGS 2.0 and, a fortiori, whether all IVF patients should be offered PGS.  
What is known already: It is clear from all experts that PGS 2.0 can be defined as biopsy at 
the blastocyst stage followed by comprehensive chromosome screening and possibly 
combined with vitrification. Most agree that mosaicism is less of an issue at the blastocyst 
stage than at the cleavage stage but whether mosaicism is no issue at all at the blastocyst 
stage is currently called into question. 
Study design, samples/materials, methods: A questionnaire was developed on the three 
major aspects of PGS 2.0: the Why, with general questions such as PGS 2.0 indications; the 
How, specifically on genetic analysis methods; the When, on the ideal method and timing of 
embryo biopsy. Thirty-five colleagues have been selected to address these questions on the 
basis of their experience with PGS, and demonstrated by peer-reviewed publications, 
presentations at meetings and participation in the discussion. The first group of experts who 
were asked about “The Why” comprised fertility experts, the second group of molecular 
biologists were asked about “The How” and the third group of embryologists were asked 
about “The When”. Furthermore, the geographical distribution of the experts has been 
taken into account. Thirty have filled in the questionnaire as well as actively participated in 
the redaction of the current paper. 
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Main results and the role of chance: The 30 participants were from Europe (Belgium, 
Germany, Greece, Italy, Netherlands, Spain, UK) and the USA. Array comparative genome 
hybridization is the most widely used method amongst the participants, but it is slowly being 
replaced by massive parallel sequencing. Most participants offering PGS 2.0 to their patients 
prefer blastocyst biopsy. The high efficiency of vitrification of blastocysts has added a layer 
of complexity to the discussion, and it is not clear whether PGS in combination with 
vitrification, PGS alone, or vitrification alone, followed by serial thawing and eSET will be the 
favoured approach. The opinions range from in favour of the introduction of PGS 2.0 for all 
IVF patients, over the proposal to use PGS as a tool to rank embryos according to their 
implantation potential, to scepticism towards PGS pending a positive outcome of robust, 
reliable and large-scale RCTs in distinct patient groups.  
Limitations, reasons for caution: Care was taken to obtain a wide spectrum of views from 
carefully chosen experts. However, not all invited experts agreed to participate, which 
explains a lack of geographical coverage in some areas, for example China. This paper is a 
collation of current practices and opinions, and it was outside the scope of this study to 
bring a scientific, once-and-for-all solution to the ongoing debate. 
Wider implications of the findings: This paper is unique in that it brings together opinions 
on PGS 2.0 from all different perspectives and gives an overview of currently applied 
technologies as well as potential future developments. It will be a useful reference for 
fertility specialists with an expertise outside reproductive genetics. 
Large scale data: none. 
Study funding and competing interest(s):No specific funding was obtained to conduct this 
questionnaire. 
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Introduction 
Preimplantation genetic screening (PGS) has been proposed since the early 1990s to 
improve IVF results. Since its early implementation, there has been a steady increase in the 
number of IVF cycles that were combined with PGS. The technology has undergone 
important developments, such as the use of fluorescence in situ hybridisation in the early 
days to massive parallel sequencing (MPS) currently, but has also had its opponents. For 
more information on the different theoretical aspects of PGS, we refer to the sister paper in 
this issue (Geraedts and Sermon, 2016). 
Methods 
Three groups of experts have been interviewed on their current practices and opinions 
regarding PGS, and more specifically on PGS in its newest form: PGS2.0. KS and JGe collated 
three questionnaires especially designed for the three major aspects of PGS2.0 (why, how 
and when). About ten colleagues have been selected per aspect as opinion leaders making 
use of the following criteria: experience with PGS, demonstrated by peer reviewed 
publications and presentations at European Society of Human Reproduction and Embryology 
(ESHRE) and American Society for Reproductive Medicine meetings, and on their vocal 
participation in the discussion. Furthermore, geographical distribution has been taken into 
account. We also took care to select experts with differing opinions. The first group consisted 
of fertility experts, who were asked about “The Why”, the second group of molecular 
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biologists were asked about “The How” and the third group of embryologists were asked 
about “The When”. The names of the respective experts, in what group they were 
interviewed and what initials were used to indicate particular experts throughout the paper 
are shown in Table 1. 
THE WHY 
For the first part, we have tried to obtain a birds’ eye view of how specialists in the field 
perceive the present and future of PGS as seen from their patients’ perspective. Since this 
part is the least technical of the three, it leaves more room for expressing opinions and 
therefore the opinions voiced are more widely spread. We have selected thirteen fertility 
experts on the basis of their publication track record, or on their vocal participation in the 
discussion, of which ten replied from seven different countries. The questions and responses 
are described below. 
For which of the following patient groups is PGS indicated? Please explain your 
choice, including why you did not chose any of the other possibilities. Why do you 
think some indications are valid, and others not?  
Repeated miscarriages (RM) and repeated implantation failure were the PGS indications that 
were most chosen by participants. This was followed by advanced maternal age (AMA), PGS 
in conjunction with PGD and single embryo transfer (SET), sometimes in young or good 
prognosis patients. Male factor infertility (MFI) and female infertility were least selected as 
appropriate indications for PGS. Two respondents (DM and FU) indicated that all IVF patients 
should be offered PGS. Other indications mentioned that were not included in the 
questionnaire were PGS in patients younger than 40 years (JC), in good prognosis patients 
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(RV) and in egg donor cycles (WV). Finally, two respondents (NG, SMa) replied that there are 
no indications for PGS. The replies per respondent are given in Table 2. 
Those respondents who are clearly in favour of PGS, having ticked four or more boxes in the 
questionnaire, list several arguments. There is the biological argument that some patient 
categories are more susceptible to produce aneuploid embryos (JD). FU takes the biological 
argument even further since even young and good prognosis patients produce aneuploid 
embryos. He states that “there is no medical reason to transfer an aneuploid embryo when 
we can detect them”. Several respondents base their judgment on RCTs (Grifo et al., 2014). 
JC mentions several small RCTs with promising results for blastocyst biopsy in conjunction 
with either array comparative hybridization (aCGH), quantitative PCR (qPCR) or MPS 
(Fiorentino et al., 2014b; Forman et al., 2013b; Richard T Scott et al., 2013). RS finds the 
rationale for PGS in a long series of RCTs providing class I data (Fiorentino et al., 2014a; 
Forman et al., 2013b; Richard T Scott et al., 2013, Chang et al., 2015), as does SMu. CS refers 
to RCTs carried out by his group for AMA and MFI that demonstrate superiority in the PGS 
group (Rubio et al., 2014; Rubio et al., 2015; Rubio et al., submitted) as well as data on RM 
using PGS 1.0 (Mastenbroek, 2013, Rubio et al., 2013). . Finally, DM offers PGS to all patients 
because pregnancy failure and particularly miscarriage causes couples to drop out and stop 
further treatment. 
A smaller group of respondents (GG, RV, WV) is more cautious, and proposes PGS in no more 
than three indications. GG proposes PGS as an additional tool to select a euploid embryo in 
PGD cycles or the single embryo to be transferred in patients with a sufficient number of 
embryos. RV agrees with the argument in favour of the SET in good prognosis patients, 
arguing that in patients who produce many embryos, the embryo loss brought about by a 
combination of blastocyst culture, embryo freezing and thawing and the false positive rate 
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of PGS should be compensated by a significantly shorter time to pregnancy. She also 
mentions patients with a long lasting infertility with no discernible cause or with RMs, 
possibly to offer the patients closure after one or two cycles with a negative PGS outcome 
and no transfer. In contrast, this respondent has a sceptical approach towards PGS for AMA: 
there are no RCTs in this population, and many patients of advanced age will produce very 
few blastocysts. Time to pregnancy, she argues, is not an issue for these patients who 
typically have only enough embryos for two transfers (Paulson, 2016). WV acknowledges 
that the risk of miscarriage or lack of implantation may be reduced per euploid embryo 
transfer, but nevertheless states that there is currently no evidence that in an unselected 
infertile patient population PGS is beneficial. 
Finally, two respondents (NG and SMa) state that there is currently insufficient evidence for 
the effectiveness of PGS (Gleicher et al., 2014; Mastenbroek and Repping, 2014) and 
therefore PGS is currently not indicated in any patient group for routine clinical use. 
Although SMa acknowledges that aneuploidy has been demonstrated in all IVF patient 
categories, he considers the biological argument insufficient grounds for routine clinical use 
which should be founded on evidence of effectiveness and safety (Dondorp and de Wert, 
2011; Ethics Comittee of the American Society for Reproductive Medicine, 2015). Moreover, 
NG points out that the biological argument may be flawed as reports are starting to emerge 
showing that “aneuploid” blastocysts can implant (Greco et al., 2015, Gleicher et al. 2015). 
Therefore we need rigorously designed clinical trials using appropriate outcome measures to 
support the hypothesis. For example, higher implantation rates after PGS are often used to 
claim that PGS increases overall success rates after IVF/ICSI, but this is incorrect as PGS is 
also associated with a lower chance of receiving a transfer and less embryos being available 
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for transfer and/or cryopreservation (Gleicher and Barad, 2012; Gleicher et al., 2014; 
Griesinger, 2016; Mastenbroek and Repping, 2014; Mastenbroek et al., 2007). 
 
What is success? 
Please explain your choice, including why you did not chose any of the other possibilities. 
Why do you prefer one definition of success to the other?  
An overview of answers can be found in Table 2. Live birth rate and reduced time-to-
pregnancy represent the best consensus on what is success. Clinical pregnancy rate is 
considered by fewer respondents, mostly because a clinical pregnancy not ending in a live 
birth is not considered success. Reduced rate of live birth with aneuploidy is considered by 
six respondents but mainly as a positive adjuvant to the other outcomes. However, two 
respondents (NG, SMa) call for caution here as PGS still shows false positives and negatives, 
and has a less than 100% accuracy, which can have far-reaching consequences in terms of 
pregnancy and live birth rates, but also the birth of trisomic children (Greco et al., 2015; 
Mastenbroek et al., 2011; Scott et al., 2012, Esfandiari et al, 2013; Gleicher et al., 2015). One 
respondent (DM) specifies that singleton live births should be preferred. A less obvious 
measure of success mentioned by CS is to use PGS as a diagnosis for patients who repeatedly 
produce aneuploid embryos only, and to offer these patients closure or other forms of 
treatment such as donation. FU sees PGS also as a means to reduce the two most important 
adverse effects in IVF treatments: miscarriages and multiple births, although the latter can 
be achieved through SET only (JGe) (Hodes-Wertz et al., 2012; Ubaldi et al., 2015). 
Respondent GG specifies that the increased live birth rate should be related to the number 
of patients starting IVF treatment. 
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Four respondents consider all measures of success listed in the questionnaire to be 
appropriate, although there is considerable disagreement on how this can be achieved. SMa 
argues that although PGS could in theory be used to improve all outcomes listed, this is not 
self-evident, because of possible harm of the biopsy (De Vos and Van Steirteghem, 2001; 
Richard T. Scott et al., 2013), mosaicism (van Echten-Arends et al., 2011), the already 
mentioned less than 100% accuracy of PGS (Mastenbroek et al., 2011, Scott et al., 2012, 
Greco et al., 2015, Esfandiari et al, 2013; Gleicher et al., 2015) and the lack of proper clinical 
evidence (Mastenbroek and Repping, 2014). This is also argued by respondent WV, who 
emphasizes that success is only achieved if PGS is not inferior in live birth rate as compared 
to IVF without PGS, and prevents implantation failure, miscarriage and aneuploid births. 
Moreover, SMa and RV argue that improved results of cryopreservation programmes 
allowing the consecutive transfer of cryopreserved embryos without compromising 
pregnancy chances could lead to cumulative pregnancy rates that are higher than without 
PGS (Mastenbroek et al., 2011, Wong et al. 2014). RV adds that PGS cannot improve the 
intrinsic quality of the cohort of embryos at hand, but allows for ranking of the embryos 
based on their chromosomal quality. Respondent JC disagrees and is uncomfortable with the 
“reduced time to pregnancy” debate: “the discussion that further PGS selection ‘does not 
matter’ because of vitrification, shows little understanding on the part of some practitioners 
to weigh emotional and economic hardship. This attitude suggests that the practice of 
transferring undiagnosed embryos (many of which are abnormal) one at a time is 
acceptable. To me this is not appropriate medical practice”. This opinion is shared by 
respondents JG and FU: “Success means to quickly reach the goal … and aneuploidies in 
embryos are the single most important factor that relates with spontaneous pregnancy 
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termination and implantation failure”. NG argues that reduced time to pregnancy may 
represent success as long as it can be shown to be cost-effective. 
What is your preferred transfer policy after PGS? Please explain your choice. Are 
there legal or other restrictions, or rationale for your choice?  
The replies of the respondents are summarized in Table 2 and are largely in agreement. 
Most respondents are in favour of elective SET (eSET) or deferred eSET in cryo cycles (JG, 
WV), and consider it standard of care and good medical practice (Grifo et al., 2013). Also 
SMa reports that in their IVF/ICSI programme SET is performed in about 70% of their cycles, 
even though PGS is not included. After PGS, arguments in favour of eSET include higher 
implantation rates (JC, JD, RS), high live birth rate (FU), avoiding multiple pregnancies (DM, 
FU) or legal restrictions (in the UK, JD). Respondent JC adds: “Frankly, with next generation 
sequencing and good internal quality control and a serious reduction of error rate, there is 
not a single group of patients where double embryo transfer (DET) is necessary.” WV is of 
the opinion that: “There is no evidence at all that higher order transfer has any benefit in 
times of PGS and vitrification.” Respondent CS uses a proprietary algorithm to personalize 
treatment and to choose between eSET and DET according to the clinical history, age, 
embryo quality and personal preference of the couple after the prediction of twin pregnancy 
is calculated. Respondent NG makes similar considerations to choose between DET or 
multiple embryo transfer, but in contrast to most respondents, does not consider twin 
pregnancies an adverse effect.  
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In which cycle do you preferably transfer? Please explain your choice. If you have 
ticked “Both”, what are the reasons to choose one or the other time of transfer?  
Our respondents show a spectrum, ranging from a more conservative preference for fresh 
transfer over a pragmatic approach choosing fresh or frozen transfer according to 
circumstances, to the transfer of frozen-warmed embryos only. The only proponent of fresh 
transfer (NG) states that frozen transfer is unsupported by credible evidence but that on the 
contrary, data suggest that fresh is almost always better than frozen (Kushnir et al., 2015). 
Respondents choosing fresh or frozen transfer according to circumstances, would do so for 
instance to avoid the risk of ovarian hyperstimulation syndrome (OHSS) in fresh cycles (GG, 
CS), depending on endometrium receptivity (RS, CS), or depending on the moment of biopsy 
whereby day 3 biopsy allows for fresh transfer, while day 5 biopsy necessitates frozen-
warmed transfer (RV). SMa uses fresh and frozen transfer sequentially. Both respondents JC 
and SMa state that it is not known yet what is best (Maheshwari and Bhattacharya, 2013; 
Mastenbroek et al., 2011; Wong et al., 2014) but mention that RCTs to show the benefit of 
fresh versus frozen embryo transfer are currently underway; JC adds that with more data in 
the near future, fresh transfer may be a thing of the past. Those respondents preferring 
transfer of frozen-thawed embryos only do so because there is more time for a PGS 
diagnosis (JD, DM, FU), reduced risk for OHSS (FU, WV), transfer in a more physiological 
endometrium and gain of implantation in a natural cycle (JD, DM, FU, WV) (Shapiro et al., 
2013, 2011).  
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Are you involved in one or more PGS trials?  
Table 3 shows which RCTs the respondents are involved in. As this question was asked to all 
three groups, and some respondents are from the same IVF centre, all replies are discussed 
in this paragraph. Two of the trials (NCT01219283 and NCT01408433) have been completed. 
However, not all the other trials are actively recruiting patients at the moment. In most 
cases there is a comparison between a PGS arm, where genetic analysis is carried out, and a 
control arm, where embryos are selected on morphological criteria only and are not analyzed 
genetically. In all except one, the ESHRE ESTEEM (ESHRE Study into The Evaluation of oocyte 
Euploidy by Microarray analysis) study (NCT01532284), in which polar body (PB) biopsy is 
performed, the intervention is performed after trophectoderm biopsy. In almost all cases 
infertility cases of a wide age group are included. 
What is according to you the best strategy for PGS? Is this strategy different from 
the one currently used in your centre?  
Many respondents consider the best strategy at this moment is to perform blastocyst biopsy 
(JD, DM, RS, CS, FU, WV) followed by comprehensive chromosome screening (CCS), which 
can be either aCGH (JD, RS, CS, WV) or qPCR (FU), and frozen eSET (DM, RS) in a natural 
cycle. RV specifies that blastocyst biopsy should be reserved for patients predicted to have 
at least four to five testable embryos. Two respondents (NG, SMa) argue that currently the 
level of evidence of published trials is insufficient to justify dissemination into clinical 
practice (Gleicher et al., 2014; Mastenbroek and Repping, 2014), and NG deplores that 
despite this fact, PGS 2.0 is widely propagated. Four respondents (JC, SMa, RV, WV) call for 
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solid RCTs, for each of the subsets of patients currently considered for PGS. MPS is seen as 
not fully validated yet, but certainly in the pipeline (RS, FU, RV). 
Would you consider changing your strategy in the future and why? 
As befits clinicians guided by evidence-based medicine, most respondents would adapt their 
current strategy if solid data would indicate that changes would benefit their patients. These 
solid data include validation and minimal error rates for different assays such as MPS (JC, JD, 
FU) and the extent to which mosaicism in human embryos affects both PGS diagnosis and 
the ability to give rise to a healthy pregnancy (RV). There is also a general call for additional 
large-scale RCTs for different patient populations showing clear clinical benefits for PGS 
outweighing the downsides and additional costs to the patients (NG, SMa, RS, FU, RV) 
(Geraedts and Sermon, this issue). The financial implications are indeed also mentioned by 
three respondents (JD, NG, CS) and may be a decisive element to expand the patient groups 
to whom PGS is offered. CS for instance would expand PGS to all IVF patients when it 
becomes affordable. This is also a future possibility for WV who would propose deferred 
eSET of blastocysts after PGS for all types of infertility, including donor embryos or embryos 
obtained from donor oocytes. One respondent (DM) considers that their current practice 
(PGS on blastocysts and eSET) avoids twins and miscarriages and should therefore not be 
changed. 
THE HOW 
In this part, we asked molecular biologists what methods they used for chromosome analysis 
in embryos. Of the twelve experts asked to participate, eleven replied. Most respondents 
use these methods for PGS, except EC and JRV who only perform PGD for structural 
chromosomal abnormalities such as translocations. Both these respondents however also 
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take into account the ploidy status of the chromosomes other than the ones involved in the 
structural chromosome abnormality. 
Which amplification method do you use? Please explain why you prefer this 
method, including why you prefer not to use other available methods. 
Most respondents use whole genome amplification (WGA) methods as a first step in CCS. 
Two respondents use qPCR primarily in preference to WGA (AC, NT) for CCS and one 
respondent (DW) uses qPCR in specific circumstances. 
There are several advantages of using WGA, either PCR-library based WGA methods such as 
Sureplex (Rubicon Genomics technology), used by EC, MDR and AH before aCGH, and by AH 
and DW before MPS, GenomePlex (Sigma Aldrich), used by NT for translocations, or multiple 
displacement amplification, used by AH before single nucleotide polymorphism (SNP) array. 
WGA yields more and highly reliable information both on full and segmental aneuploidies 
(CR, JG, SMu, DW) and for instance allows the combination of a PGD for a monogenic disease 
or structural chromosomal aberration together with a CCS (FF, EC, JRV, SMu), it leaves 
archived material for re-testing in case of misdiagnosis, or the need for additional 
information (AH, DW), and finally has been widely validated (MDR, FF, AH)(Fiorentino et al., 
2011; Gutiérrez-Mateo et al., 2011; Scott et al., 2012)(Schoolcraft et al. 2012). Storage of 
amplified material is now part of the accreditation process of many (commercial) labs (AH). 
Two respondents (AC, NT) use WGA followed by SNP array exclusively for structural 
chromosomal abnormalities where resolution below the whole chromosome, and therefore 
SNP array, is necessary.  
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1. Which method do you use for comprehensive chromosome screening? 
AC exclusively uses qPCR for conventional PGS cases because it is extensively validated 
(Capalbo et al., 2015a; Forman et al., 2013b; Richard T Scott et al., 2013a; Treff et al., 2012), 
flexible, faster and less expensive. For instance, specific primers can be added to the qPCR 
mix when a monogenic disease needs to be diagnosed in conjunction with the PGS 
(Zimmerman et al., 2015). This respondent also mentions chromosome-specific amplification 
bias introduced as a disadvantage of WGA (Capalbo et al., 2015a), and claims that WGA 
methods are not properly validated, which is contradicted by several other respondents 
(MDR, FF). NT also prefers qPCR for the same reasons of speed, reliability and low cost. He 
and his group have validated the method extensively (Scott et al., 2013, Forman et al., 
2013a). DW uses qPCR in a minority of cases where the clinic wishes to perform 
trophectoderm biopsy followed by fresh transfer early in the morning of day 6 and where 
the quick turn-around time and the lower cost are of essence. qPCR however only allows for 
the analyses of whole chromosomes and not for segmental abnormalities, but this is 
mentioned as an advantage by respondent AC rather than a disadvantage.  
Most respondents use aCGH as a very robust and well-validated gold standard (Jacobs et al., 
2014), which however is quickly being overtaken by MPS methods (Deleye et al., 2015; 
Fiorentino, 2012). Array-CGH allows analysis of all chromosomes as well as segmental 
abnormalities of certain sizes (see also question 3) and can be applied both at the single cell 
level, such as on PBs and cleavage-stage blastomeres, as well as multiple cells obtained at 
the blastocyst stage. It has a quick turn-around time of about 24h and can therefore be used 
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in a fresh cycle. However, it is less efficient at detecting mosaicism in blastocyst biopsies and 
is quickly becoming more expensive than MPS (DW).  
MPS has already been introduced by a number of respondents (Bono et al., 2015; Fiorentino 
et al., 2015, 2014a, 2014b; Kung et al., 2015; Vera-Rodríguez et al., 2016; Wells et al., 2014) 
while several other respondents report that they are in the process of introducing it in their 
centres (MDR, EC, JRV). The cost of MPS is dropping quickly as the method allows for far-
reaching automation and high-throughput. Moreover, the level of detection is such that in 
one run whole chromosome abnormalities, segmental abnormalities, (un)balanced 
translocations, single gene disorders and even mitochondrial disorders can potentially be 
diagnosed. Four respondents mention it as the only method that will enable detection of 
low-grade mosaicism in blastocyst biopsies (FF, JGr, SMu, DW); however respondent JRV 
adds that haplarithmisis, a method for concurrent aneuploidy screening and genotyping 
using SNP arrays (Zamani Esteki et al., 2015), is also able to do so. MPS can be performed 
within the time frame of a blastocyst biopsy and fresh transfer; however mostly in order to 
obtain cost savings, such as the need for full capacity runs of the sequencer, MPS is usually 
proposed in frozen cycles (DW).  
Four participants have indicated that they use SNP arrays either for karyomapping (AH, JGr, 
SMu, DW)(Konstantinidis et al., 2015) or for haplarithmisis (Zamani Esteki et al., 2015)(JRV). 
However both AH as DW have indicated that they consider MPS to be the better option, and 
two other respondents (EC, MDR) mention that they have considered SNP analysis, but will 
move directly to MPS because of the higher financial implications for the implementation of 
SNP analysis and because karyomapping has limitations in the detection of copy number 
aberrations  (MDR). 
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Which abnormalities do you score?  
Especially if you score segmental abnormalities, please explain why you have chosen to 
score (or not) these abnormalities. What are the consequences for diagnosis of the 
embryo? Is it scored abnormal, or would you still consider transfer? 
Unsurprisingly, all respondents answered that they score whole chromosome abnormalities. 
However, while a majority score mosaics, few report it back (SMu, DW) while others will 
categorize the mosaic embryo as either normal or abnormal depending on the level of 
mosaicism. Segmental abnormalities are scored by even more respondents, including those 
stating that they only use array-based assays for PGD for structural abnormalities (Table 4).  
There is significant variation in opinion on whether mosaic embryos should be transferred or 
not. Firstly, detection levels vary significantly between technologies and it is clear that aCGH 
is less suitable for establishing exact levels of (low) mosaicism than MPS (FF, JGr, SMu, DW) 
(Munné et al., 2016). Secondly, the true clinical significance of mosaicism is still unclear. Two 
respondents, FF and NG, demonstrated that mosaic embryos can grow into healthy euploid 
newborns (Greco et al., 2015, Gleicher et al., 2015). Moreover, respondent NT states that 
mosaicism can only be established after two separate biopsies, as the frequency of 
mosaicism due to technical artefacts can easily be overestimated. 
Segmental aneuploidies are even more the subject of debate. Respondent AC, who does not 
score segmental abnormalities, states that the role and incidence in preimplantation 
embryos is still not well established and remains controversial. Uncertainty of diagnosis and 
difficulties in clinical management remain until positive and negative clinical predictive 
values can be established, with a risk that reproductively competent embryos are 
erroneously discarded owing to false aneuploidy calls. NT shares this opinion: “it should be 
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considered unethical to use a test which results in discarding an embryo without having first 
proven that it has true predictive value for a negative clinical outcome” (Chow et al., 2014; 
Mertzanidou et al., 2013b; Treff et al., 2012, 2010). JRV, who performs PGD for structural 
aberrations on blastomere biopsies, would transfer embryos with segmental anomalies 
unrelated to the question. However, SMu argues that if these methods are used to detect 
unbalanced translocations, those found “de novo” should have the same risk of producing 
abnormal babies and reduced viability as those resulting from translocations. It could be 
considered that “de novo” segmental abnormality identification has been previously 
validated during the work done on translocations. It should however also be noted that 
inherited translocations are present in all cells, while postzygotic segmental abnormalities 
may be present in a small percentage of the embryo’s cells (KS)(Mertzanidou et al., 2013a). 
Given these uncertainties that are clearly acknowledged by all, most respondents will use a 
pragmatic approach in dealing with segmental aneuploidies. Some will only recommend not 
to transfer embryos with very clear and large abnormalities, involving for example a whole 
chromosome arm, or defects >15Mb (CR). Some will use the information to rank the 
embryos (JRV, EC) or will take into consideration the size, type of copy number variant (CNV) 
and gene content (FF). Viable aneuploidies, such as those involving chromosomes 13, 18 and 
21, are treated with extreme caution (EC, FF). Finally, several respondents include genetic 
counselling to help patients reach a decision (FF, MDR, AH, SMu, DW) and in case of transfer, 
let patients sign an informed consent (MDR) and/or strongly recommend prenatal diagnosis 
(AH, DW). 
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Is there a general policy (eg for prenatal samples) for segmental abnormalities in your 
centre? 
Only five respondents mention that they have a specific policy for segmental abnormalities 
identified during prenatal diagnosis (EC, MDR, FF, CR, JRV). EC, FF, MDR and JRV evaluate the 
risk case by case according to the size of the CNV, whether it is a loss or gain, and the gene 
content, and MDR and JRV follow guidelines as used by Belgian genetic centres (Vanakker et 
al., 2014). CR only carries out prenatal diagnosis using arrays if there are specific ultrasound 
findings. Other respondents do not offer prenatal diagnosis. 
If partial deletions and duplications are detected: which is the minimal size? 
The complete answers can be found in Table 4. Generally, the minimal size is smaller for 
known segmental aberrations such as translocations. The sizes range between >1Mb (SMu) 
and >20Mb (EC, MDR). For translocations, >5Mb is a recurring figure (CR, NT, JRV, DW). 
How many hours after obtaining the sample are your results available?  
An overview of the answers can be found in Table 4. Respondents using qPCR need less than 
4h to have results (AC, NT, DW). Respondents using aCGH need somewhere between 12 and 
24h (FF, AH, SMu, DW) or 24-48h (EC, CR, JRV). MPS requires even longer (48h or more) and 
is therefore typically used in conjunction with frozen cycles. MDR specifies that they analyse 
many samples together for reasons of economy, cryopreserve the embryos, and inform the 
patients that the results will be ready in 2 weeks, in time for a warming cycle.  
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THE WHEN 
Nine clinical embryologists with expertise in embryo biopsy were asked about their views on 
current practices; eight, working in seven different countries, replied. PGS is offered in all IVF 
centres where the respondents are based. 
Which type of material do you use for PGS? Please explain why you prefer this 
method, including why you prefer not to use other available methods.  
PB biopsy is only carried out by three respondents: ADV and GK use it within the framework 
of the ESTEEM RCT only (see Table 2), while MMo is limited by legal restrictions, as 
trophectoderm biopsy is only allowed in certified centres in Germany. PB biopsy is less 
invasive than cleavage stage biopsy and avoids the issue of mosaicism (GK). As a main 
disadvantage of PB biopsy, several respondents (MMe, KSc, JS) mention the fact that no 
paternal information is obtained. Other disadvantages mentioned are the cost (JH), 
fragmentation of the PBs at biopsy (JS) and small amount of genetic material for analysis 
(JS). 
MMe is the only respondent who still performs blastomere biopsy, although he mentions 
that his centre is moving toward trophectoderm biopsy. This respondent claims to have 
similar results with both blastomere and trophectoderm biopsy, and with more chances for 
transfer with the former. However, this respondent agrees that the efficiency is greater with 
trophectoderm biopsy as fewer embryos need to be analysed that have a greater chance to 
be euploid. Other respondents consider that the disadvantages of blastomere biopsy 
outweigh the advantages: mosaicism present at the cleavage stage (GK, ADV, JH, JS) 
(Mertzanidou et al., 2013b) and lower implantation rates (KSc) (Richard T. Scott et al., 2013). 
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One respondent (JS) considers that the disadvantages of blastomere biopsy are sufficient 
and critical and that blastomere biopsy at day 3 should be abandoned. 
Most respondents prefer blastocyst biopsy for the following reasons: (1) it is less damaging 
to the embryo than blastomere biopsy (ADV, GK, LR, KSc, JS) (Richard T. Scott et al., 2013), 
(2) yields more material for genetic analysis (ADV, GK, MMe, LR, JS) (Capalbo et al., 2015b; 
Jones et al., 2008), thereby also (3) avoiding or decreasing issues with mosaicism (ADV, GK, 
JH, LR, JS) (Capalbo et al., 2013). Moreover, only viable embryos are analysed (LR). All these 
elements taken together leads to an increased predictive positive value for blastocyst biopsy 
(Scott et al., 2012). LR concludes that one RCT (Lee et al., 2015) and one meta-analysis 
(Dahdouh et al., 2015) have recently demonstrated the effectiveness of this approach, and 
believes that to date this is the only validated approach. 
Blastocoele fluid (BF) biopsy is mostly considered too new and not validated (JH, GK, LR, KSc, 
JS). Respondent JS: “while a few preliminary studies and at least one published study (Tobler 
et al., 2015) point to the presence of genomic DNA in the fluid, there appear to be problems 
in terms of correlation of the blastocoele DNA and the chromosome status of the embryo”. 
During the writing of this manuscript, results from a longitudinal cohort study comparing 
aCGH on cell biopsies and BF were published, concluding that if the proportion of clinically 
useful BFs is improved, blastocentesis could become the preferred source of DNA for 
chromosomal testing (Magli et al., 2015). 
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If applicable, which method of biopsying both polar bodies, do you prefer? Please 
explain why you prefer this method, including why you prefer not to use other 
available methods. 
Three respondents did not reply to this question as they indicated that they did not perform 
PB biopsy. Three more respondents indicated that they performed simultaneous PBI and II 
biopsy, because it was specified in the ESTEEM study (see Table 3) (ADV, GK), and because 
simultaneous biopsy can be carried out in a minimum of time with a minimum of 
manipulation (GK, MMo). JH and KSc would prefer sequential biopsy, although neither uses 
PB biopsy routinely because the risk for degradation of the DNA of the first PB is lower (KSc) 
and because it takes less time (JH). MMo notes that sequential PB biopsy can be preferred 
when a highly fragmented PB1 is already present at time of ICSI. 
At what time after ICSI do you perform the biopsy(ies)?  
The ESTEEM study requires that the PB biopsy is carried out around 9h post ICSI, which is 
why this is the preferred time for ADV and GK. MMo extends this to an earlier timing, from 
7-9h post ICSI. Four respondents indicated the timing of blastomere biopsy, usually at day 3 
between 64 and 72h. The timing for blastocyst biopsy varies widely, from early day 5 (115-
116h) to day 5 and 6 (up to 142 -150h) and even day 7. 
Which method do you use for zona breaching? 
Please explain why you prefer this method, including why you prefer not to use other 
available methods:  
Zona breaching using the laser is preferred by all respondents who offer an extensive list of 
advantages. Laser zona breaching is fast and allows making small holes in a controlled and 
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standardised manner. This is particularly important for blastocyst biopsy where a small hole 
is made on day 3 or 4, allowing the embryo to herniate about 2 days later without 
completely going out of the zona. Inner call mass (ICM) herniation is not considered an issue, 
as it occurs in less than 10% of biopsied blastocysts (ADV) and in any case can be solved by 
making a second zona opening on the opposite site of the herniating ICM (ADV, JS). One 
respondent (LR) has developed a biopsy method with simultaneous zona breaching and 
trophectoderm aspiration and biopsy (Capalbo et al., 2014). It is also safer for the embryo 
because the time out of the incubator is limited (KSc, GK, JS) and because it avoids the 
possible damage and even embryo rupture that can be caused by acid Tyrode’s zona 
breaching (MMo, JS). Finally, it is technically less demanding and requires less training (JS). 
For those using PB biopsy (GK, MMo), using acid Tyrode’s is out of the question, and 
mechanical zona breaching takes more time to perform. Although laser zona breaching can 
be considered safe since many children have been born after its use (ADV)(Desmyttere et al., 
2012), there has been at least one report of negative effects (Honguntikar et al., 2015). 
However, respondents do not refer to these negative reports and seem to accept zona 
breaching with laser as the safest method available. 
In which culture medium do you biopsy? 
Please explain why you prefer this method, including why you prefer not to use other 
available methods.  
Both PB and blastocyst biopsy is carried out in standard culture medium. This is considered 
least detrimental to the embryo, avoiding an additional stressor (LR, KSc, JS) and it also 
avoids additional variables that would need to be assessed for quality control (JS). All 
respondents indicating that they use, or have used, blastomere biopsy responded that they 
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use Ca2+Mg2+-free medium to loosen cell-to-cell contacts in the cleavage stage embryo. 
Some (JH, MMo) buffer standard culture media with HEPES to allow for better pH control 
during manipulation. 
Would you consider alternative biopsy types (eg if you do cleavage stage biopsy, 
would you change to blastocyst)? If not, why not (legal restrictions, logistic 
problems, cost…)? 
Three respondents are in transition from cleavage stage biopsy to blastocyst biopsy: ADV for 
PGD for monogenic diseases, and MMe and MMo for PGS. Blastomere biopsy is considered 
“going back” (JS). Two respondents (LR, KSc) who use blastocyst biopsy exclusively would 
consider blastocoele biopsy on the condition that strong evidence in favour is available (LR) 
because it is less invasive for the embryo (KSc). JS proposes a two pronuclei (2PN) banking 
approach to compile a sufficient number of 2PNs to grow to blastocysts for biopsy. 
What do you do with undiagnosed embryos? Please explain why you choose this 
course of action? Are there legal or other restrictions that determine your decision-
making process?  
One respondent (MMo) transfers undiagnosed embryos after obtaining informed patient 
consent. Most respondents indicate that they re-biopsy the embryo and try to get a 
diagnosis from the second sample. For one respondent (ADV) this is a rare occurrence as 
their chosen course of action after PGS is to transfer undiagnosed embryos after genetic 
counselling and obtaining informed consent from the patient. The majority of respondents 
however routinely rebiopsy embryos, if necessary followed by cryopreservation (JH, GK, 
MMe, LR, JS). One respondent (LR) indicated that qPCR is used on frozen-thawed 
undiagnosed blastocysts for a quick turn-around time. If after re-analysis there is still no 
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diagnosis or patients refuse a second biopsy, GK, MMe and JS would transfer the 
undiagnosed embryos, after consultation with the patients and their doctor (MMe). 
THE FUTURE OF PGS 
All three groups were asked what they considered would be the next major breakthroughs, 
and how PGS would develop in the future. These technological developments could lead to 
new applications such as non-invasive PGS through spent media assessment (JC, CS) or 
disease susceptibility screening of embryos, as is currently carried out in newborns, e.g. 
inborn errors of metabolism such as phenylketonuria, and hypothyroidism (GG). New ways 
to assess the embryo that go beyond genomics, such as transcriptomics (GK)(Jones et al., 
2008), as yet undetermined metabolomics biomarkers (MMe, LR, KSc, RS), epigenomics (RV) 
or mitochondrial content, constitution, structure and function (GK, MMe, CS, KSc, RV) (Diez-
Juan et al., 2015; Fragouli et al., 2015), will be developed. Of course, these will need 
extensive validation prior to clinical application (KSc). 
These could then help to add nuances to our evaluation of embryo fitness, and they might 
help in refining our current embryo ranking strategy (RV) and to identify the euploid embryo 
most likely to achieve a viable pregnancy (DM).  
However, several respondents add a cautionary note to these innovations. SMa calls for 
rigorously designed trials on the new PGS technologies, a position endorsed by ADV, GK, 
MMe and RV. SMa: “…stakeholders with potential commercial interests (are known to) have 
an effect on the design and reporting of clinical studies with the aim to (mis)use science for 
marketing purposes (Gøtzsche et al., 2007; Macleod et al., 2014; Psaty and Kronmal, 2008; 
Ross et al., 2008). Clinicians should no longer leave the liability in PGS to the ‘demand of the 
patient’, but take up the challenge of determining by proper science the true value of PGS 
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before introducing the technique in routine clinical practice.” MMe adds a nuance to this 
position: “more RCT´s would be ideal, but, most of them (well designed) are logistically 
impossible (a huge number of patients are needed) or unethical (existing retrospective 
evidence makes it difficult to allocate patients in the control group knowing that they would 
have lower chances to become pregnant…)”. 
RV also cautions that a more generalized switch to genome sequencing and an increased 
resolution of genome readings will bring about a significant increase in the acquisition of 
genomic data of unknown significance with respect to embryonic health. She therefore calls 
for continued basic research in the genetics of development and implantation, a position 
endorsed by EC, JG, CS, RS, CR and JRV. 
NG looks at the future from a completely different angle: “PGS is, of course, an embryo 
selection method. In my opinion, it is time to challenge the whole concept of embryo 
selection… for two reasons: one, it biologically makes little sense, considering that the 
embryos we select from are the product of up to 4 months of follicle maturation, and egg 
quality represents ca. 95% of embryo quality. … If we want to have a real impact, we have to 
start intervening in early stages of follicle maturation to really affect egg and embryo quality; 
Two, every embryo selection method in the literature, …(have)… outcome data almost 
exclusively reported with as a reference point embryo transfer, rather than by “intent to 
treat” (cycle start). When outcomes are generalized in this fashion, especially poor prognosis 
patients are usually outright harmed, and that applies to all embryo selection methods, 
including PGS (Griesinger, 2016).” 
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CONCLUSION 
The initiators of this questionnaire, KS and JGe, were pleasantly surprised by the positive 
response from those invited to participate: of the 35 experts invited, 30 responded. Of note 
is that no Chinese experts replied to our questionnaire, although two were invited.  
Consensus is lacking on which patient groups, if any at all, can benefit from PGS 2.0, and a 
fortiori whether all IVF patients should be offered PGS. The high efficiency of vitrification of 
blastocysts has added a layer of complexity to the discussion, and it is not clear whether it 
will be a story of PGS in combination with vitrification, or of PGS alone, or vitrification alone, 
followed by serial thawing and eSET. The opinions range from in favour of the introduction 
of PGS 2.0 for all IVF patients, over the proposal to use PGS as a tool to rank embryos 
according to their implantation potential, to scepticism towards PGS pending a positive 
outcome of robust, reliable and large-scale RCTs in distinct patient groups. This latter group 
is not against PGS per se, but they oppose routine clinical introduction of a technique of as 
yet unknown efficacy. However, although a number of respondents have called for solid 
RCTs, separately for each of the subsets of patients currently considered for PGS, these are 
not underway. In ongoing RCTs, mostly all types of infertility and all age groups are included. 
Furthermore, the variation of molecular methods used is limited and all except one RCT use 
trophectoderm biopsies. 
Therefore, although it is clear from all three groups of experts that PGS 2.0 can be defined as 
biopsy at the blastocyst stage followed by CCS and possibly combined with vitrification, 
experimental evidence for the safety and efficacy of PGS 2.0 needs to be awaited. There is 
agreement on the fact that mosaicism is less of an issue at the blastocyst stage than at the 
cleavage stage but whether mosaicism is no issue at all at the blastocyst stage is currently 
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called into question. BF biopsy seems an attractive alternative as it is deemed less invasive, 
although experts are awaiting validation and translation to the clinic. The CCS method 
however is in full evolution: while aCGH is the most widely used method amongst our 
participants, combining ease-of-use with high information content, it is slowly being 
replaced by MPS (De Rycke et al., 2015). SNP arrays and qPCR, both with their specific 
advantages and disadvantages, will follow suit. 
Finally, our expert group is also looking to the future, and most see CCS as only one stop on 
the road to fully understanding the biology of the human preimplantation embryo. This 
understanding could be broadened by the analysis of the transcriptome, the epigenome, the 
metabolome and the mitochondrial function of embryos. A combination of all these 
elements may in the future allow fertility specialists to predict which embryo in a cohort will 
have the highest chance of implantation – or even predict with absolute accuracy whether 
an embryo will implant or not. This evolution would greatly benefit our patients, for whom 
the physical, emotional, financial burden and time spent will be reduced to the minimum. 
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Table 1: Experts who participated in a study on ‘the why, the how and the when’ of 
preimplantation genetic screening (PGS) 2.0. 
 
 
Fertility specialists (initials 
used in text) 
Molecular biologists 
(initials used in text) 
Embryologists (initials 
used in text) 
J. Cohen (JC) USA A. Capalbo 
(AC) 
Italy A. De Vos 
(ADV) 
Belgium 
J. Delhanty 
(JD) 
UK E. Coonen 
(EC) 
The 
Netherlands 
J. Harper (JH) UK 
N. Gleicher 
(NG) 
USA M. De 
Rycke 
(MDR) 
Belgium G. Kokkali 
(GK) 
Greece 
G. Griesinger 
(GG) 
Germany F. 
Fiorentino 
(FF) 
Italy M. Meseguer 
(MMe) 
Spain 
S. 
Mastenbroek 
(SMa) 
The 
Netherlands 
J. Grifo (JG) USA M. Montag 
(MMo) 
Germany 
D. Meldrum 
(DM) 
USA A. 
Handyside 
(AH) 
UK L. Rienzi (LR) Italy 
R. Scott (RS) USA S. Munné 
(SMu) 
USA K. Scott (KSc) USA 
C. Simon 
(CS) 
Spain C. Rubio 
(CR) 
Spain J. Swain (JS) USA 
F. Ubaldi 
(FU) 
Italy N. Treff 
(NT) 
USA   
R. Vassena 
(RV) 
Spain J.R. 
Vermeesch 
(JRV) 
Belgium   
W. Verpoest 
(WV) 
Belgium D. Wells 
(DW) 
UK   
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Table 2: The Why. Replies to questions for fertility specialists. 
Answers JC JD NG GG SMa DM RS CS FU RV WV 
Q1: For which of the following patient groups is PGS indicated? *Other, see text 
Advanced Maternal Age   X    X X X X  X 
Female Infertility       X X  X   
Male Factor Infertility   X    X X  X   
Repeated implantation failure  X X    X X X X X X 
Repeated Miscarriage  X X    X X X X X X 
PGD X   X  X X X X   
Single Embryo Transfer -SET X   X  X X  X   
Other* X     X   X X X 
Q2: What is success? *Other, see text 
Clinical pregnancy X X   X X X X X   
Live birth X X X X X X X X X  X 
Less aneuploidy X    X X X X   X 
Reduced time to pregnancy X  X X X X X X X X X 
Other* X   X X X  X X   
Q3: What is your preferred transfer policy after PGS? *Other: see text 
SET X X  X  X X  X X X 
Double embryo transfer   X         
Multiple embryo transfer   X         
Other*     X   X    
Q4: In which cycle do you preferably transfer? 
Fresh   X         
Frozen  X    X   X  X 
Both X   X X  X X  X  
Q5: Are you involved in one or more PGS trials? Type of trials are detailed in Table 3. 
Yes X   X   X X X  X 
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Table 3: List of PGS RCTs the respondents are involved in 
Trial number Trial title Fertility specialists Molecular biologists Embryologists 
ISRCTN81216689 Trial evaluating the influence of morphology and developmental 
rate on euploid blastocysts ongoing implantation rate 
FU AC LR 
NCT01219283 Study of the Efficacy of 24 Chromosome Preimplantation 
Genetic Diagnosis (PGD) 
RS  KSc 
NCT01408433 Single Embryo Transfer of a Euploid Embryo Versus Double 
Embryo Transfer 
RS NT KSc 
NCT01532284 ESHRE Study into The Evaluation of oocyte Euploidy by 
Microarray analysis (ESTEEM) 
WV, GG MDR ADV, GK 
NCT01571076 Preimplantation Genetic Screening (PGS) in Advanced Female 
Age and Male Severe Factor 
CS CR  
NCT01917240 Sequential vs. Monophasic Media Impact Trial (SuMMIT)  NT  
NCT01946945 Comparison of Standard ART Practice vs. Trophectoderm 
Biopsy and Whole Chromosome Analysis 
JC SMu, DW  
NCT01977144 Screening of Low Responders for Aneuploidy to Improve 
Reproductive Efficiency (Solaire) 
 NT  
NCT02000349 Comparison of Frozen-thawed Embryo Transfers and Fresh 
Embryo Transfers With Whole Chromosome Analysis Using 
Next Generation Sequencing 
JC SMu, DW  
NCT02032264 Next Generation Sequencing Screening for Embryonic Ploidy 
Status (nexgen) 
RS NT KSc 
NCT02268786 Single Embryo TrAnsfeR of Euploid Embryo (STAR) JC SMu, DW  
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Table 4: The How. Replies to questions for molecular biologists 
 
Answer AC EC MDR FF JG AH SMu CR NT JRV DW 
Q1: Which amplification method do you use? 
whole genome amplification   X X X X X X X  X X 
quantitative PCR - qPCR X        X  X 
Q2: Which method do you use for comprehensive chromosome screening? CGH: comparative genome hybridisation  
fluorescence in situ hybridisation  - - - - - - - - - - - 
metaphase-CGH - - - - - - - - - - - 
Array- CGH - aCGH (X) X X X X X X X   X 
Single Nucleotide Polymorphism      X X X  X X X 
Massive parallel sequencing – MPS    X X X X X   X 
Q3: Which abnormalities do you score? 
Whole chromosome X X X X X X X X X X X 
Mosaicism   X X X X X   X X 
Segmentals  X X X X X X X  X X 
Q4: If partial deletions and duplications are detected: which is the minimal size? * in PGD for translocations, + de 
novo, ° aCGH, $ MPS 
1-5Mb     X°  X°    X 
>5 Mb     X$  X$  X* X*  
>10 Mb  X*      X*    
> 20 Mb  X+ X+     X+    
Q5: How many hours after obtaining the sample are your results available? * after qPCR, + after aCGH, ° after MPS 
4h* X        X  X 
12-24h    X  X X    X+ 
24-48h  X      X  X  
Freeze all   X  X      X° 
Q6: Are you involved in one or more PGS trial? Type of trials are detailed in Table 3. 
Yes X  X    X X X  X 
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 Table 5: The When. Replies to questions for embryologists 
Answer ADV GK JH MMe MMo LR KSc JS 
Q1: Which type of DNA source material do you use for PGS? 
Polar body X X   X    
Blastomere    X     
Trophectoderm X X X X  X X X 
Blastocoelic fluid - - - - - - - - 
Q2: If applicable, which method of biopsying both polar bodies, do you prefer? 
Simultaneous X X   X    
Sequential   X    X  
Q3: At what time after ICSI do you perform the biopsy(ies)? 
Polar body 9h 9-10h 12-16h  7-9h    
Blastomere 70h 64-72h 64-72h 68-70h     
Trophectoderm D5, D6 106-110h 115h 116-120h  D5-7 112-150h 118-142h 
Blastocoelic fluid - - - - - - - - 
Q4: Which method do you use for zona breaching? 
Laser X X X X X X X X 
Mechanical - - - - - - - - 
Acid Tyrode’s - - - - - - - - 
Q5: In which culture medium do you biopsy? * With HEPES added; ° Only for blastomere biopsy 
Standard culture medium X X X* X X* X X X 
Ca2+-Mg2--free° X X X X     
Q7: What do you do with undiagnosed embryos? See text for more details 
Discard - - - - - - - - 
Transfer X    X    
Rebiopsy  X X X  X X X 
Q8: Are you involved in one or more PGS trial? Type of trials are detailed in Table 3. 
Yes X X    X X  
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